Current investigations are evaluating composite predictive models incorporating TROP-2 immunohistochemistry (IHC) scoring (64), ADC internalization efficiency (65), CD8+ T cell infiltration levels (66), and dynamic changes in circulating tumor DNA (ctDNA) (67) to better predict treatment sensitivity. Here, CD8A is linked to neoplasm.